Skip to main content
. 2014 Aug 29;13(12):5325–5332. doi: 10.1021/pr500753r

Figure 1.

Figure 1

National Cancer Institute—Clinical Proteomic Technologies for Cancer Initiative’s restructured biomarker development pipeline. The incorporation of a verification step based on MRM–MS or iMRM–MS multiplexed assays into the current biomarker development pipeline between discovery and validation is beneficial for streamlining the transition of protein discovery candidates to large-scale clinical trials commonly validated by immunoassays.